Trans-resveratrol oral - Jupiter Orphan Therapeutics

Drug Profile

Trans-resveratrol oral - Jupiter Orphan Therapeutics

Alternative Names: JOT 101; JOT 102; JOT 104; JOT 105; JOT 106; JOTROL

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jupiter Orphan Therapeutics
  • Developer Jupiter Orphan Therapeutics; Mayo Clinic; Murdoch Childrens Research Institute; Universidade de Coimbra
  • Class Antineoplastics; Antithrombotics; Cardiovascular therapies; Nonsteroidal anti-inflammatories; Phenols; Small molecules; Stilbenes; Vasodilators
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Ribonucleotide reductase inhibitors; SIRT1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Friedreich's ataxia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Friedreich's ataxia
  • Phase I Mucopolysaccharidosis I
  • Preclinical Pancreatic cancer; Spinocerebellar degeneration

Most Recent Events

  • 22 Aug 2017 Trans-resveratrol oral - Jupiter Orphan Therapeutics receives Orphan Drug status for Friedreich's ataxia in USA
  • 22 Aug 2017 Primary endpoints were met in the phase II trial in Friedreich's ataxia
  • 23 Jan 2017 Phase-I clinical trials in Mucopolysaccharidosis I (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top